Chengda Pharmaceutical (301201.SZ) released its performance for the first half of the year, with a net income of 25.1748 million yuan, a decrease of 14.23%.

Zhitong Finance · Aug 27 15:59

Chengda Pharmaceuticals (301201.SZ) released its semi-annual report for 2024, with the company's revenue at 0.164 billion...

Zhītōng Cáijīng APP News, Chengda Pharmaceuticals (301201.SZ) released its semi-annual report for 2024, with the company's revenue at 0.164 billion yuan, a decrease of 1.55% year-on-year. The net income attributable to the shareholders of the listed company was 25.1748 million yuan, a decrease of 14.23% year-on-year. The net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 3.164 million yuan, a decrease of 80.18% year-on-year. The basic earnings per share was 0.165 yuan.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

诚达药业(301201.SZ)发布上半年业绩，净利润2517.48万元，下降14.23%

Chengda Pharmaceutical (301201.SZ) released its performance for the first half of the year, with a net income of 25.1748 million yuan, a decrease of 14.23%.

Risk Disclaimer

Statement